8VP1 Stock Chart & Stats
€0.03
>-€0.01(-7.41%)
At close: 4:00 PM EDT
€0.03
>-€0.01(-7.41%)
Day’s Range― - ―
52-Week Range€0.02 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.76M
Enterprise Value€6.88
Total Cash (Recent Filing)€210.30K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding101,289,665
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)13.00
Price to Sales (P/S)9.49
P/FCF Ratio-5.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageEssentially no debt limits interest obligations and reduces balance-sheet risk. This gives Avricore greater flexibility to stabilize operations, invest in HealthTab, or pursue partnerships without the immediate constraints of a leveraged capital structure.
Pharmacy-Based Digital Health PlatformHealthTab is embedded in community-pharmacy testing workflows, creating a platform model with potential recurring usage and program revenue. Broader adoption of decentralized diagnostics and digital reporting could support long-term relevance if execution improves.
Prior Operating Cash Flow And Revenue RampEarlier positive operating cash flow and revenue expansion indicate the model has previously generated commercial traction. That history provides evidence of potential operating leverage, although renewed growth and improved cost control are needed to restore sustainability.
Bears Say
Severe Revenue ContractionThe sharp TTM revenue decline signals weak demand, reduced program activity, or execution difficulties. Sustained contraction would limit HealthTab’s network effects, reduce operating leverage, and make it harder to cover fixed technology and corporate costs.
Deepening Losses And Negative Gross ProfitLarge losses relative to revenue and negative TTM gross profit indicate that pricing, volume mix, or direct costs are undermining the economics of the platform. Without a durable improvement, growth could increase rather than reduce the company’s funding needs.
Cash Burn And Shrinking EquityPersistent cash consumption alongside a much smaller equity base raises dependence on external financing. If operations do not recover, future funding may require dilution or unfavorable terms, limiting strategic flexibility and shareholder value creation.
Avricore Health News
8VP1 FAQ
What was Avricore Health Inc.’s price range in the past 12 months?
Avricore Health Inc. lowest stock price was €0.02 and its highest was €0.05 in the past 12 months.
What is Avricore Health Inc.’s market cap?
Avricore Health Inc.’s market cap is €3.76M.
When is Avricore Health Inc.’s upcoming earnings report date?
Avricore Health Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 5 days.
How were Avricore Health Inc.’s earnings last quarter?
Currently, no data Available
Is Avricore Health Inc. overvalued?
According to Wall Street analysts Avricore Health Inc.’s price is currently Overvalued.
Does Avricore Health Inc. pay dividends?
Avricore Health Inc. does not currently pay dividends.
What is Avricore Health Inc.’s EPS estimate?
Avricore Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avricore Health Inc. have?
Avricore Health Inc. has 101,289,665 shares outstanding.
What happened to Avricore Health Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avricore Health Inc.?
Currently, no hedge funds are holding shares in DE:8VP1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avricore Health Inc.
Avricore Health Inc. operates within Canada, specializing in health data management and point-of-care technological solutions. Their primary offering is HealthTab, a precise, laboratory-quality diagnostic testing system designed for use in pharmacies. This enterprise maintains key alliances with prominent organizations such as Shoppers Drug Marts and Abbott. Established in 1996 and headquartered in Vancouver, Canada, the company previously operated as Vanc Pharmaceuticals Inc., adopting its current name, Avricore Health Inc., in October 2018.
Technical Analysis
BioMark Diagnostics
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
―
PanGenomic Health, Inc. Class A
―